Edinburgh- and Boston-based rehabilitation technology startup Bioliberty has raised €2.95 million ($3.3 million) in a Series A extension. With this latest funding, the company’s total funding has reached €12.07 million ($13.5 million).
The funding round welcomed four new investors: TGH Ventures, the investment arm of Tampa General Hospital; Ballad Ventures; Belfast-based Whiterock; and 25m Health.
“This funding and our new strategic investors are crucial to our next phase: creating a more connected rehabilitation journey. We want to connect data across the patient journey, extend our technology into the home, and use AI to further augment therapy and assessment for physical and occupational therapists,” said Rowan Armstrong, co-founder and CEO, Bioliberty.
Bioliberty was founded in 2020 by Armstrong, Ross O’Hanlon, Conan Bradley and Shéa Quinn, who are from Northern Ireland. The company develops robotic rehabilitation technology to help patients recover movement and strength in their upper body, especially those who have suffered strokes or other neurological conditions that affect mobility.
The company’s technology includes three main products. Lifehub is a portable control unit that powers the system and provides interactive therapy sessions. Lifeglov is a soft robotic glove that uses air pressure to help patients open and strengthen their hands.
The third product, Lifemind, is a digital dashboard designed for healthcare professionals. It brings therapy data together in one place and uses artificial intelligence (AI) to automatically prepare clinical notes. Lifehub and Lifeglov are FDA-listed in the US, where Bioliberty started selling its products commercially in 2025.
Bioliberty says it developed its technology in partnership with leading rehabilitation centres. Its system allows therapists to start treatment sessions in less than five minutes. It also helps patients complete more exercise repetitions during each session, supporting their recovery process.
“Bioliberty has been implemented by our therapists seamlessly. Patients are excited to see gains in their function and enjoy the interactivity of the tasks and games they can access,” said Ethan Clark, Therapy Manager, Methodist Rehabilitation Hospital.
Bioliberty aims to make sure patients can continue their recovery even after leaving a rehabilitation centre. The company wants to provide technology that supports patients throughout their recovery journey, both inside and outside healthcare facilities.
With its US base in Boston, Bioliberty has built partnerships with several major rehabilitation providers across the country. In 2024, it also conducted a clinical study with the Mount Sinai Health System. The company aims to build a complete rehabilitation platform that supports patients in hospitals, care facilities and their own homes.
